Şunu aradınız:: firxa tad dati: (Maltaca - İngilizce)

il-firxa tad-densità;
density range;

il-firxa tad-distribuzzjoni (1.1.1)
distributional range (1.1.1)

firxa tad-dimensjonijiet tal-vettura (totali):.
range of vehicle dimensions (overall):

il-firxa tad-danni presunti għandhom jkun li ġej:
assumed extent of damage shall be as follows:

dawn li ġejjin jaqgħu barra mill-firxa tad-direttiva:
the following are excluded from the scope of the directive: financial services,

perjeta wera farmakokinetika lineari fil-firxa tad-doża rakkomandata.
perjeta displayed linear pharmacokinetics within the recommended dose range.

sommarju tad-dati ewlenin tal-bidla
key changeover dates at a glance

tad-dati tar-reviżjoni tal-permessi,
the review dates of the permits,

o huma ġejjin mill-ħażna u l-firxa tad-demel ta’
(mainly cows and sheep); i mate cl

il-firxa tad-dimensjonijiet tal-vettura (b’mod globali)
range of vehicle dimensions (overall)

il- farmakokinetika ta’ silodosin hija lineari tul din il-firxa tad-doża.
the pharmacokinetics of silodosin is linear throughout this dose range.

lura għall-bidu sommarju tad-dati ewlenin tal-bidla
key changeover dates at a glance 

dwar il-bdil tad-dati stabbiliti fl-artikolu 56;
modify the dates laid down in article 56;

il- firxa tad- doża tista ’ tvarja bejn 1 u 10 400 mg pillola ma ’ kull ikla.
the dose range may vary between 1 and 10 capsules per meal.

il-firxa tad-doża tista’ tvarja bejn 1 u 5 pilloli ta’ 800 mg ma’ kull ikla.
the dose range may vary between 1 and 5 tablets of 800 mg per meal.

fil-firxa tad-dożi kliniċi, valdecoxib huwa impeditur selettiv cyclooxygenase-2 (cox-2).
valdecoxib is a selective cyclooxygenase-2 (cox-2) inhibitor within the clinical dose range.

jogħġbok għamel nota tad- dati meta l- aħħar kont eżaminat għat- tb hawn taħt.
please record the dates of the last screening

struzzjonijiet biex iżżomm rekord tal-postijiet fejn tagħti l-injezzjoni u tad-dati.
instructions for keeping track of your injection sites and dates

hemm relazzjoni linejari bejn id-doża mogħtija u l-konċentrazzjoni fil-plażma osservata fil-firxa tad- doża terapewtika.
there is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs.

artikolu 50 ukoll iddeċiżjoni ta’ċaħda bl-indikazzjoni tad-dati tal-preżentata u tannotifika.
article 50 by the decision rejecting the complaint together with the dates on which the complaint was submitted and the decision notified.